STC signs Women’s Empowerment Principles of UN

The WEPs document was submitted in the presence of Maha Al-Nuhait, general manager of sustainability program at STC, and Janneke van der Graaff-Kukler, deputy regional director at UN Women.
Short Url
Updated 17 March 2020

STC signs Women’s Empowerment Principles of UN

As part of the Sustainable Stock Exchanges (SSE) initiative “Ring the Bell for Gender Equality,” STC has signed the UN Women’s Empowerment Principles (WEPs). The event was organized by Saudi stock exchange Tadawul, on the occasion of International Women’s Day. The WEPs document was submitted in the presence of Maha Al-Nuhait, general manager of sustainability program at STC, and Janneke van der Graaff-Kukler, deputy regional director at UN Women.
The SSE initiative has five pillars of activity: Partnerships to achieve goals, climate action, responsible consumption and production, decent work and economic growth, and gender equality.
“STC’s interaction with International Women’s Day confirms the company’s commitment to achieving sustainable development goals and implementing best sustainability practices in the company by supporting Saudi women and allowing them to hold executive positions,” a statement said.
The telecom operator previously launched the first board to empower women and enhance their participation in the market. This stems from the company’s belief in the importance of investing in its employees and providing them with the best opportunities to develop their skills and knowledge. The move is in line with Saudi Arabia’s Vision 2030, and STC’s commitment to the National Transformation Program, which aims to increase Saudi women’s contribution to economic growth.


Clinical trials to accelerate adoption of new drug treatments in Saudi Arabia

Updated 27 May 2020

Clinical trials to accelerate adoption of new drug treatments in Saudi Arabia

  • Trials are being led locally as an essential means to verify the safety and effectiveness of a new drug
  • Eli Lilly has a major role to play during the coronavirus disease (COVID-19) pandemic

RIYADH: Clinical trials in Saudi Arabia could speed up the adoption of new drugs locally, a pharmaceutical executive has told Arab News.

“Clinical trials have two very big benefits for the Kingdom. Firstly, they provide data in the long run with respect to safety and efficacy, catered specifically to the Saudi population. Secondly, they impact local investment and build healthcare capabilities,” Managing Director of Eli Lilly Dimitri Livadas said..

Lividas further explained that the clinical trial phase of any new treatment is crucial as it represents the stage between the adoption or rejection of a drug. Working with the Ministry of Health and with a presence in the Kingdom for 42 years, the pharmaceutical company began research trials in the country in 2016, consisting of five pre-marketing activities and three monitoring studies for post-marketing.

Lividas added that the trials are being led locally as an essential means to verify the safety and effectiveness of a new drug before it is put to the market and introduced to patients. The majority of these are focused on diabetes, oncology, immunology, and osteoporosis.

“We genuinely believe that our future is here in Saudi Arabia. We continue to make great progress in having a commercial organization in the Kingdom that is fully staffed by Saudi nationals,” said Lividas.

As a biopharmaceutical company, Eli Lilly has a major role to play during the coronavirus disease (COVID-19) pandemic. It recently announced partnership with AbCellera to develop a treatment for the virus and aims to enter into clinical trials this year.

“I salute the Saudi authorities for their strong measures to contain the spread of COVID-19. I think it is an example to the world on how to do this. I would like to also express my gratitude toward all healthcare professionals who are currently on the frontlines, risking their own health to help others," Lividas said.